Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients
Open Access
- 28 November 2020
- journal article
- research article
- Published by Wiley in Journal of Oncology
- Vol. 2020, 1-7
Abstract
Introduction. Advances in genomic techniques have been valuable in guiding decisions regarding the treatment of early breast cancer (EBC) patients. These multigene assays include Oncotype DX, Prosigna, and Endopredict. There has generally been a tendency to overtreat or undertreat patients, and having reliable prognostic factors could significantly improve rates of appropriate treatment administration. In this study, we showcase the impact of genomic tests on adjuvant treatment decisions in EBC patients. Materials and Methods. This is a retrospective study that includes EBC patients treated between December 2016 and February 2018. The physicians choice of treatment was recorded before and after obtaining the results of the genomics tests. Baseline demographics and pathological data were collected from medical records. Results. A total of 75 patients were included. Fifty patients underwent Oncotype DX genomic analysis, 11 patients underwent Prosigna analysis, and 14 patients underwent Endopredict analysis. A total of 21 physicians plans (28) were initially undecided and then carried out after obtaining genomic test results. 13 patients were planned to undergo endocrine therapy alone, while 8 were planned to undergo both endocrine therapy and chemotherapy. Treatment was changed in 26 patients (34.67). The decision to deescalate therapy was taken in 19 patients (25.33). The decision to escalate treatment was made in 7 patients (9.33). Conclusion. Our study demonstrates the importance of genomics testing, as it assisted physicians in avoiding unnecessary adjuvant chemotherapy in 25.33 of patients, thus reducing side effects of chemotherapy and the financial burden on patients.Keywords
Funding Information
- Centre National de la Recherche Scientifique (#103257)
This publication has 27 references indexed in Scilit:
- Taxane benefit in breast cancer—a role for grade and chromosomal stabilityNature Reviews Clinical Oncology, 2013
- Conveying genomic recurrence risk estimates to patients with early‐stage breast cancer: oncologist perspectivesPsycho-Oncology, 2013
- Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: Association With Responsiveness to Anthracycline-Based ChemotherapyJournal of Clinical Oncology, 2011
- Complementary Value of the Ki-67 Proliferation Index to the Oncotype DX Recurrence ScoreInternational Journal of Surgical Pathology, 2009
- Histopathologic variables predict Oncotype DX™ Recurrence ScoreLaboratory Investigation, 2008
- Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical TrialsJournal of Clinical Oncology, 2008
- HER2and Responsiveness of Breast Cancer to Adjuvant ChemotherapyNew England Journal of Medicine, 2006
- Retrospective Analysis of Topoisomerase IIa Amplifications and Deletions As Predictive Markers in Primary Breast Cancer Patients Randomly Assigned to Cyclophosphamide, Methotrexate, and Fluorouracil or Cyclophosphamide, Epirubicin, and Fluorouracil: Danish Breast Cancer Cooperative GroupJournal of Clinical Oncology, 2005
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Topoisomerase II-α (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapyEuropean Journal of Cancer, 2003